文献速递血液净化与透析慢性肾脏病

美国血液透析患者中依特卡肽的使用、剂量滴定与CKD-MBD标志物反应

Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients.
PubMed 文献 · Am J Kidney Dis · 2021-07-15

本研究基于美国DOPPS前瞻性队列中2596例新使用依特卡肽的成人维持性血液透析患者,描述2017年4月至2019年8月期间依特卡肽的使用、剂量、疗效及停药情况。结果显示,启动后12个月内平均PTH下降40%,PTH达标比例从33%升至64%,停药率在3、6、12个月分别为9%、17%、27%。

要点

  • 依特卡肽处方量至2019年8月增至透析患者的6%,70%起始剂量为15 mg/wk。
  • 启动后12个月平均PTH从948降至566 pg/mL,降幅40%,达标比例从33%升至64%。
  • 3、6、12个月停药率分别为9%、17%、27%,血磷>5.5 mg/dL比例从55%降至45%。

核心结论

  • 启动依特卡肽后12个月内PTH水平大幅且持续下降,支持其作为实现KDIGO推荐的CKD-MBD标志物目标的有效疗法。

研究设计与样本

  • 前瞻性队列中的新用户设计,纳入美国DOPPS中2017年4月至2019年8月2596例新使用依特卡肽的成人维持性血液透析患者。

主要发现

  • 至2019年8月依特卡肽处方增至透析患者的6%,起始剂量15 mg/wk占70%、7.5 mg/wk占27%,49%新用户在 prior 3个月内用过西那卡塞。
  • 停药率3个月9%、6个月17%、12个月27%。
  • 12个月时平均PTH从948降至566 pg/mL(降40%),PTH达标(150-599 pg/mL)比例从33%升至64%;基线PTH≥600 pg/mL者从0升至60%, prior 西那卡塞使用者从30%升至63%。
  • 血磷>5.5 mg/dL比例从55%降至45%,白蛋白校正血钙<7.5 mg/dL的患病率保持在1%-2%。
  • 启动后12个月内活性维生素D使用从77%升至87%,含钙磷结合剂从41%升至50%。

临床怎么用

  • 依特卡肽可用于血液透析患者以降低PTH并提高达标率,需关注12个月内约27%的停药率及血钙、血磷变化。

局限性

  • 缺乏提供者剂量方案、暂停剂量或停药原因的数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Clinical trial data have demonstrated the efficacy of etelcalcetide for reducing parathyroid hormone (PTH) levels in hemodialysis (HD) patients. We provide a real-world summary of etelcalcetide utilization, dosing, effectiveness, and discontinuation since its US introduction in April 2017. STUDY DESIGN: New-user design within prospective cohort. SETTING & PARTICIPANTS: 2,596 new users of etelcalcetide from April 2017 through August 2019 in a national sample of adult maintenance HD patients in the US Dialysis Outcomes and Practice Patterns Study (DOPPS). PREDICTORS: Baseline PTH, prior cinacalcet use, initial etelcalcetide dose. OUTCOME: Trajectories of etelcalcetide dose, chronic kidney disease-mineral and bone disease (CKD-MBD) medications, and levels of PTH, serum calcium, and phosphorus in the 12 months after etelcalcetide initiation. ANALYTICAL APPROACH: Cumulative incidence methods for etelcalcetide discontinuation and linear generalized estimating equations for trajectory analyses. RESULTS: By August 2019, etelcalcetide prescriptions increased to 6% of HD patients from their first use in April 2017. Starting etelcalcetide dose was 15 mg/wk in 70% of patients and 7.5 mg/wk in 27% of patients; 49% of new users were prescribed cinacalcet in the prior 3 months. Etelcalcetide discontinuation was 9%, 17%, and 27% by 3, 6, and 12 months after initiation. One year after etelcalcetide initiation, mean PTH levels declined by 40%, from 948 to 566 pg/mL, and the proportion of patients with PTH within target (150-599 pg/mL) increased from 33% to 64% overall, from 0 to 60% among patients with baseline PTH ≥ 600 pg/mL, and from 30% to 63% among patients with prior cinacalcet use. The proportion of patients with serum phosphorus > 5.5 mg/dL decreased from 55% to 45%, while the prevalence of albumin-corrected serum calcium < 7.5 mg/dL remained at 1%-2%. There were increases in use of active vitamin D (from 77% to 87%) and calcium-based phosphate binders (from 41% to 50%) in the 12 months after etelcalcetide initiation. LIMITATIONS: Data are unavailable for provider dosing protocols, dose holds, or reasons for discontinuation. CONCLUSIONS: In the 12 months after etelcalcetide initiation, patients had large and sustained reductions in PTH levels. These results support the utility of etelcalcetide as an effective therapy to achieve the KDIGO-recommended guidelines for CKD-MBD markers in HD patients.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Karaboyas A, Muenz D, Fuller DS, et al. Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients. Am J Kidney Dis. 2021. PMID: 34273436. doi:10.1053/j.ajkd.2021.05.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。